Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Banchi

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Investigational New Drugs|January 17, 2025
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathwayMarta Banchi, Maria Christina Cox, Arianna Bandini, et al.
Investigational New Drugs|June 3, 2019
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cellsPaola Orlandi, Daniela Gentile, Marta Banchi, et al.
Investigational New Drugs|October 18, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cellsArianna Bandini, Letizia Biso, Cristina Viaggi, et al.
ACS Pharmacology & Translational Science|December 14, 2023
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone SynthaseAnnachiara Tinivella, Marta Banchi, Guido Gambacorta, et al.
Cancers|January 28, 2026
Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective AnalysisSabrina Pelliccia, Marta Banchi, Lucrezia De Marchi, et al.
Pharmacological Research|June 9, 2022
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patientsFederico Cucchiara, Giacomo Luci, Noemi Giannini, et al.
Archiv Der Pharmazie|July 29, 2022
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effectsMarco Robello, Silvia Salerno, Elisabetta Barresi, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2020
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphomaMaria Christina Cox, Marta Banchi, Sabrina Pelliccia, et al.
Pharmacological Research|May 29, 2020
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancerTeresa Di Desidero, Paola Orlandi, Daniela Gentile, et al.
Journal of Clinical Medicine|February 26, 2025
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In VivoArianna Bandini, Marta Banchi, Paola Orlandi, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|January 17, 2025
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathwayMarta Banchi, Maria Christina Cox, Arianna Bandini, et al.
Investigational New Drugs|June 3, 2019
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cellsPaola Orlandi, Daniela Gentile, Marta Banchi, et al.
Investigational New Drugs|October 18, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cellsArianna Bandini, Letizia Biso, Cristina Viaggi, et al.
ACS Pharmacology & Translational Science|December 14, 2023
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone SynthaseAnnachiara Tinivella, Marta Banchi, Guido Gambacorta, et al.
Cancers|January 28, 2026
Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective AnalysisSabrina Pelliccia, Marta Banchi, Lucrezia De Marchi, et al.
Pharmacological Research|June 9, 2022
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patientsFederico Cucchiara, Giacomo Luci, Noemi Giannini, et al.
Archiv Der Pharmazie|July 29, 2022
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effectsMarco Robello, Silvia Salerno, Elisabetta Barresi, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2020
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphomaMaria Christina Cox, Marta Banchi, Sabrina Pelliccia, et al.
Pharmacological Research|May 29, 2020
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancerTeresa Di Desidero, Paola Orlandi, Daniela Gentile, et al.
Journal of Clinical Medicine|February 26, 2025
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In VivoArianna Bandini, Marta Banchi, Paola Orlandi, et al.
Pageof 3